On 13 February, AstraZeneca signed the Memorandums of Understanding (MOUs) at the Singapore Treasury, in the presence of Singapore’s Minister for Trade and Industry, Mr. Chan Chun Sing, Swedish Ambassador to Singapore, H.E. Mr. Niclas Kvarnström and H.E. Mrs. Kara Owen, British High Commissioner to Singapore.
AstraZeneca signed these partnerships with Singapore’s AI start-up eko.ai, the SingHealth Duke-NUS Academic Medical Centre (AMC) and the Agency for Science, Technology and Research (A*STAR) to drive better health outcomes and create new economic opportunities in Singapore by leveraging artificial intelligence (AI), big data and genomics.
Along with our partners, AstraZeneca aims to support and contribute to Singapore’s innovation initiatives, such as the National AI Strategy, which is a key step in Singapore’s aim to becoming a Smart Nation. By supporting the growth of talent and skills, and speeding up the deployment of digital technology, these partnerships will advance Singapore’s position as a global hub for cutting edge biomedical and health science innovation and create economic opportunities.
H.E. Mr. Niclas Kvarnström, Swedish Ambassador to Singapore, said “In Sweden we have a long tradition of close collaboration between government, academia and industry for innovation that delivers tangible benefits where it matters most: to people’s lives. I am proud that AstraZeneca, which has been a cornerstone of Swedish healthcare innovation for decades, and its Singapore partners bring this vision into practice by applying their world-class expertise to improve the lives of people.”
H.E. Mrs. Kara Owen, British High Commissioner to Singapore, said, “The UK has a world-class health and life sciences ecosystem that puts it at the forefront of digital health and medical technology breakthroughs. Our strong public-private ethos continues to drive the next generation of life-changing treatments, cutting-edge technologies and customer-first services – not just in the UK but worldwide. This collaboration between British-Swedish AstraZeneca, eko.ai, the SingHealth Duke-NUS Academic Medical Centre (AMC) and A*STAR is one brilliant example of the many forward-looking and innovative collaborations between the UK and Singapore.”
The partnerships will also lead to better health outcomes for the people of Singapore, by using technology to identify risk factors for disease prevention and earlier diagnosis, and to improve the treatment and management of chronic diseases such as diabetes and cancer.
In Singapore’s National AI Strategy, chronic disease prediction and management has been identified as one of five key National AI projects. As a global, science-led biopharmaceutical company AstraZeneca is a well-positioned partner for Singapore’s Smart Nation efforts.
Through AstraZeneca’s strategic R&D centres in Sweden, the UK and the US, AI, data science and digital technology are applied to accelerate R&D, personalise treatment, and improve patient outcomes as well as healthcare delivery.
AstraZeneca has been active in developing healthcare innovation partnerships in Europe and Emerging Markets such as China, Russia and Argentina. This has led to the creation of AstraZeneca health innovation hubs around the world, which are a unique opportunity for our Singaporean partners to showcase their world-class solutions and connect with leading biomedical innovation ecosystems abroad.
Together with our partners, AstraZeneca aims to transform healthcare and give more patients access to new digital healthcare solutions that can revolutionise the management of challenging diseases such as cancer, diabetes, heart failure and respiratory diseases.
.svg)
